Carregant...

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset fro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Neurol Disord
Autor principal: Khatri, Bhupendra O.
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784254/
https://ncbi.nlm.nih.gov/pubmed/27006700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616628766
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!